Virally infected hematopoietic cells and uses thereof
US9623096B2 · kind B2 · utility
0Cited by
1References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 8, 2012 |
| Grant date | Apr 18, 2017 |
| Priority date | — |
| Expiry date | Feb 17, 2033 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/36032
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An immunogenic formulation for a patient, the formulation includes virus-modulated hematopoietic cancer cells, where the modulated hematopoietic cancer cells are generated from viable hematopoietic cancer cells obtained from the patient, either isolated or in a mixed hematopoietic population of healthy and cancer cells, and where the viable hematopoietic cancer cells are infected ex vivo with a virus that modulates the expression of a plurality of endogenous immune regulatory molecules to increase the immunogenicity of the hematopoietic cancer cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.